{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:02:46Z","timestamp":1789506166682,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15357-5","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:28:01Z","timestamp":1768991281000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrative transcriptomic profiling reveals subtype-specific therapeutic vulnerabilities and resistance mechanisms in prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Wei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"15357_CR1","doi-asserted-by":"crossref","unstructured":"Fleshner NE, Alibhai SMH, Connelly KA, et al. Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. Ther adv med oncol. 2023;15:17588359231152845.","DOI":"10.1177\/17588359231152845"},{"key":"15357_CR2","doi-asserted-by":"crossref","unstructured":"Zacharias N, Lee J, Ramachandran S, et al. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol imaging biol. 2019;21(1):86\u201394.","DOI":"10.1007\/s11307-018-1199-6"},{"key":"15357_CR3","unstructured":"Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer disc. 2011;1(6):487\u221295."},{"key":"15357_CR4","doi-asserted-by":"crossref","unstructured":"Fritz V, Benfodda Z, Henriquet C, et al. Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth. Oncogene. 2013;32(42):5101\u221210.","DOI":"10.1038\/onc.2012.523"},{"key":"15357_CR5","doi-asserted-by":"crossref","unstructured":"Jadvar H. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. J nuclear medicine : official publication, Society of Nucl Med. 2016;57(Suppl 3):25s\u20139s.","DOI":"10.2967\/jnumed.115.170704"},{"key":"15357_CR6","doi-asserted-by":"crossref","unstructured":"Lei H, Wang Z, Jiang D, et al. CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. Cell death & disease, 2021;12(8):740.","DOI":"10.1038\/s41419-021-04027-6"},{"key":"15357_CR7","doi-asserted-by":"crossref","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, et al. Defining a Cancer Dependency Map. Cell, 2017;170(3):564\u221276.e16.","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"15357_CR8","unstructured":"Li J, Xu C, Lee HJ, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nat. 2020;580(7801): 93\u22129."},{"key":"15357_CR9","unstructured":"Gr\u00f6bner\u00a0SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nat. 2018;555(7696):321\u22127."},{"key":"15357_CR10","doi-asserted-by":"crossref","unstructured":"Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer cell, 2005;8(5):393\u2013406.","DOI":"10.1016\/j.ccr.2005.10.001"},{"key":"15357_CR11","doi-asserted-by":"crossref","unstructured":"Cai C, Wang H, He HH, et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. The J clinical invest. 2013;123(3):1109\u221222.","DOI":"10.1172\/JCI66666"},{"key":"15357_CR12","doi-asserted-by":"crossref","unstructured":"Bolis M, Bossi D, Vallerga A, et al. Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression. Nat commun. 2021;12(1):7033.","DOI":"10.1038\/s41467-021-26840-5"},{"key":"15357_CR13","doi-asserted-by":"crossref","unstructured":"Crowell PD, Giafaglione JM, Jones AE, et al. MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell reports, 2023;42(10):113221.","DOI":"10.1016\/j.celrep.2023.113221"},{"key":"15357_CR14","doi-asserted-by":"crossref","unstructured":"White RE, 3rd, Bannister M, Day A, et al. Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC. Front oncol. 2023;13:1210487.","DOI":"10.3389\/fonc.2023.1210487"},{"key":"15357_CR15","doi-asserted-by":"publisher","unstructured":"Suominen MI, Knuuttila M, Schatz CA, et al. Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. Internal j mol sci. 2023;24(3):21892023;24(3).\u00a0https:\/\/doi.org\/10.3390\/ijms24032189.","DOI":"10.3390\/ijms24032189"},{"key":"15357_CR16","doi-asserted-by":"crossref","unstructured":"Qian C, Yang Q, Rotinen M, et al. ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer. Nucleic acids res. 2024;52(13):7740\u221260.","DOI":"10.1093\/nar\/gkae547"},{"key":"15357_CR17","doi-asserted-by":"crossref","unstructured":"Knuuttila M, Mehmood A, Huhtaniemi R, et al. Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts. The Amer j pathol. 2018;188(1):216\u221228.","DOI":"10.1016\/j.ajpath.2017.08.036"},{"key":"15357_CR18","doi-asserted-by":"crossref","unstructured":"Dong B, Miao J, Wang Y, et al. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer. Commun biol. 2020;3(1): 778.","DOI":"10.1038\/s42003-020-01476-1"},{"key":"15357_CR19","doi-asserted-by":"crossref","unstructured":"Taavitsainen S, Engedal N, Cao S, et al. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat commun. 2021;12(1):5307.","DOI":"10.1038\/s41467-021-25624-1"},{"key":"15357_CR20","doi-asserted-by":"crossref","unstructured":"Kiviaho A, Eerola SK, Kallio HM L, et al. Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer. Nat commun. 2024;15(1):9949.","DOI":"10.1038\/s41467-024-54364-1"},{"key":"15357_CR21","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a ca j clinic. 2017;67(1):7\u201330.","DOI":"10.3322\/caac.21387"},{"key":"15357_CR22","doi-asserted-by":"crossref","unstructured":"Nguyen-Nielsen M, Borre M. Diagnostic and Therapeutic Strategies for Prostate Cancer. Sem nucl med. 2016;46(6):484\u221290.","DOI":"10.1053\/j.semnuclmed.2016.07.002"},{"key":"15357_CR23","doi-asserted-by":"crossref","unstructured":"Spratt DE, Malone S, Roy S, et al. Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. Journal of clinical oncology : official journal of the Amer Soc Clinic Oncol. 2021;39(2):136\u221244.","DOI":"10.1200\/JCO.20.02438"},{"key":"15357_CR24","unstructured":"Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England j med. 2013;368(2):138\u221248."},{"key":"15357_CR25","doi-asserted-by":"crossref","unstructured":"Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat rev Can. 2015;15(12):701\u221211.","DOI":"10.1038\/nrc4016"},{"key":"15357_CR26","doi-asserted-by":"crossref","unstructured":"Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England j med. 2012;367(13):1187\u201397.","DOI":"10.1056\/NEJMoa1207506"},{"key":"15357_CR27","doi-asserted-by":"crossref","unstructured":"Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Annals of oncology : official j Eur Soc Med Oncol. 2019;30(11):1813\u201320.","DOI":"10.1093\/annonc\/mdz397"},{"key":"15357_CR28","doi-asserted-by":"crossref","unstructured":"Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat rev Drug disc. 2015;14(2):130\u221246.","DOI":"10.1038\/nrd4504"},{"key":"15357_CR29","doi-asserted-by":"crossref","unstructured":"Gupta S, Argil\u00e9s\u00a0G, Munster PN, et al. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical cancer research : an official j Amer Assoc Ca Res. 2015;21(23):5235\u221244.","DOI":"10.1158\/1078-0432.CCR-15-0180"},{"key":"15357_CR30","doi-asserted-by":"crossref","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell, 2012;149(2):274\u2009\u2212\u200993.","DOI":"10.1016\/j.cell.2012.03.017"},{"key":"15357_CR31","doi-asserted-by":"crossref","unstructured":"Tewari D, Patni P, Bishayee A, et al. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Sem ca biol. 2022;80:1\u201317.","DOI":"10.1016\/j.semcancer.2019.12.008"},{"key":"15357_CR32","doi-asserted-by":"publisher","unstructured":"Gujrati H, Ha S, Waseem M, et al. Downregulation of miR-99b-5p and Upregulation of Nuclear mTOR Cooperatively Promotes the Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer. Internal J Mol Scie. 2022;23(17):9643.\u00a0https:\/\/doi.org\/10.3390\/ijms23179643.","DOI":"10.3390\/ijms23179643"},{"key":"15357_CR33","doi-asserted-by":"crossref","unstructured":"Mcnair C, Urbanucci A, Comstock CE, et al. Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 2017;36(12):1655\u221268.","DOI":"10.1038\/onc.2016.334"},{"key":"15357_CR34","doi-asserted-by":"crossref","unstructured":"Yeh Y, Guo Q, Connelly Z, et al. Wnt\/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance. Adv exp med biol. 2019;1210:351\u221278.","DOI":"10.1007\/978-3-030-32656-2_16"},{"key":"15357_CR35","doi-asserted-by":"crossref","unstructured":"Einstein DJ, Arai S, Balk SP. Targeting the androgen receptor and overcoming resistance in prostate cancer. Curr opinion oncol. 2019;31(3):175\u2009\u2212\u200982.","DOI":"10.1097\/CCO.0000000000000520"},{"key":"15357_CR36","doi-asserted-by":"crossref","unstructured":"Santer FR, Erb HH, Oh SJ, et al. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget. 2015;6(8):6105\u221222.","DOI":"10.18632\/oncotarget.3368"},{"key":"15357_CR37","doi-asserted-by":"crossref","unstructured":"Pasqualini L, Bu H, Puhr M, et al. miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer. Mol endocrinol (Baltimore, Md), 2015;29(7):1037\u221254.","DOI":"10.1210\/me.2014-1358"},{"key":"15357_CR38","doi-asserted-by":"publisher","unstructured":"Hogh-Binder SA, Klein D, Wolfsperger F, et al. Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy. Can. 2023;15(9):2496.\u00a0https:\/\/doi.org\/10.3390\/cancers15092496.","DOI":"10.3390\/cancers15092496"},{"key":"15357_CR39","doi-asserted-by":"crossref","unstructured":"Hirai S, Tada M, Yamaguchi M, et al. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival. Biochem biophysical res commun. 2020;526(2):417\u2009\u2212\u200923.","DOI":"10.1016\/j.bbrc.2020.03.116"},{"key":"15357_CR40","doi-asserted-by":"crossref","unstructured":"Xie Y, Han X, Yu J, et al. EGR3 and estrone are involved in the tamoxifen resistance and progression of breast cancer. J ca res clin oncol. 2023;149(20):18103\u221217.","DOI":"10.1007\/s00432-023-05503-6"},{"key":"15357_CR41","doi-asserted-by":"crossref","unstructured":"Wei G, Margolin AA, Haery L, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Ca cell. 2012;21(4):547\u221262.","DOI":"10.1016\/j.ccr.2012.02.028"},{"key":"15357_CR42","doi-asserted-by":"crossref","unstructured":"Duan L, Tadi MJ, O\u2019Hara KM, et al. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells. The J biol chem. 2024;300(6):107375.","DOI":"10.1016\/j.jbc.2024.107375"},{"key":"15357_CR43","doi-asserted-by":"crossref","unstructured":"Handle F, Prekovic S, Helsen C, et al. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Sci rep. 2019;9(1):13786.","DOI":"10.1038\/s41598-019-50220-1"},{"key":"15357_CR44","doi-asserted-by":"crossref","unstructured":"Tambe P, Salve R, Choudhary P, et al. Targeted silencing of the MCL-1 gene using multi-layered dendrimer-based nanoconstructs achieves efficient tumor regression in xenografted mice models. Internal j pharm. 2023;634:122659.","DOI":"10.1016\/j.ijpharm.2023.122659"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15357-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15357-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:28:11Z","timestamp":1768991291000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15357-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15357"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15357-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}